Recent Updates
Recently added Catalysts
LUCD Positive Sentiment

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023

Key Takeaway: Lucid Diagnostics Inc. has announced a business update conference call and webcast scheduled for August 15, 2023. During this event, CEO Lishan Aklog will discuss the company's operations and growth strategy, while CFO Dennis McGrath will present the financial results for the second quarter of 2023. The call emphasizes Lucid's commitment to cancer prevention and early detection in patients at risk of esophageal issues. Interested parties can access the call via a dedicated phone line or through the company’s website.
Price reaction · baseline $1.37 (2023-07-28 close) · clean, no other LUCD news in the window
day 0 close · peak
+2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics will provide important business updates in the upcoming call.
  • The company's focus on cancer prevention and early detection is a significant health advancement.
  • CEO Lishan Aklog and CFO Dennis McGrath will present detailed information on operations and financial results.

Full Press Release Details

Conference Call and Webcast at 8:30AM Eastern Time
NEW YORK, July 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, August 15, 2023, at 8:30 AM EST. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second-quarter 2023 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-833-816-1418 and international listeners should dial 1-412-317-0511. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Frequently Asked Questions

When will Lucid Diagnostics host its conference call?

Lucid Diagnostics will host its conference call on August 15, 2023, at 8:30 AM EST.

Who will lead the business update call?

Lishan Aklog, M.D., the CEO, will lead the business update call.

How can I access the conference call?

You can access it via phone or the webcast on luciddx.com.

What will be discussed during the call?

The call will cover the company's operations and second-quarter financial results.

Is there a replay of the conference call available?

Yes, a replay will be available for 30 days on the company's investor relations website.

Last updated: Jul 31, 2023